MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MapLight Therapeutics, Inc. - Common Stock (NQ:MPLT)

13.31 +0.34 (+2.62%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MapLight Therapeutics, Inc. - Common Stock

News headline image
MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Therapeutics Announces $150 Million Private Placement Financing
From MapLight Therapeutics, Inc.
Via GlobeNewswire
Top movers analysis one hour before the close of the markets on 2026-07-29: top gainers and losers in today's session. ↗
Via Chartmill
Traders are paying attention to the gapping stocks in Wednesday's session. ↗
Via Chartmill
Which stocks are moving on Monday? ↗
Via Chartmill
News headline image
Maplight Therapeutics’ Schizophrenia Drug Hits Phase II Primary Endpoint ↗
Maplight Therapeutics (NASDAQ:MPLT) reported that its Phase II ZEPHYR trial of ML-007C-MA met its primary endpoint in schizophrenia, with the twice-daily regimen producing a statistically significant... 
Via MarketBeat
Monday's session: top gainers and losers ↗
Via Chartmill
News headline image
MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law
From Schall, Brown & Schwartz LLP
Via Business Wire
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
These stocks that are showing activity before the opening bell on Monday. ↗
Via Chartmill
News headline image
MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Therapeutics Announces Changes to Board of Directors
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles ↗
Oculis advances late-stage topical therapies for diabetic and neuro-ophthalmic eye diseases in the clinical-stage biotech sector. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million ↗
Mineralys Therapeutics develops novel therapies for resistant hypertension, with its lead candidate advancing through clinical trials. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge ↗
This clinical-stage biotech develops small molecule therapies for cancer and fibrotic diseases, focusing on galectin-3 and LOXL2 inhibitors. 
Via The Motley Fool
News headline image
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean ↗
Dyne Therapeutics targets rare muscle diseases with its FORCE platform, aiming to meet unmet needs in neuromuscular therapeutics. 
Via The Motley Fool
News headline image
MapLight's CFO Just Sold 36,000 Shares for $1 Million. Is It a Buy, Sell, or Hold? ↗
This clinical-stage biotech focused on CNS disorders reported a notable insider sale amid ongoing development of its neurology pipeline. 
Via The Motley Fool
Topics Derivatives Regulatory Compliance
News headline image
MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Therapeutics to Participate in Upcoming Investor Conferences
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
This MapLight Insider Sold 69,000 Shares for $2.1 Million at the End of April ↗
This clinical-stage biotech focused on CNS disorders reported a notable insider sale in its latest SEC filing. 
Via The Motley Fool
Topics Derivatives Regulatory Compliance
News headline image
MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
What a 1% Insider Sale of MPLT Stock Signals Ahead of 2026 Trial Data ↗
This clinical-stage biotech focused on CNS disorders reported a notable insider sale, as disclosed in its latest SEC filing. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Therapeutics to Participate in Upcoming Investor Conferences
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer’s Disease Psychosis
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From MapLight Therapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story